# US 10,369,220 B2 · Methods and compositions for affecting immunological responsiveness

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,369,220 B2
- Document ID: US10369220B2
- Status: Granted
- Kind: B2
- Application number: 15/724,586
- Filed: 2017-10-04
- Published: 2018-04-05
- Granted: 2019-08-06
- Earliest claimed: 2016-10-04
- Assignees: CellPrint IP Holding, LLC
- Applicants: CellPrint IP Holding, LLC
- Inventors: David R. Kaplan
- Web page: https://patentgrep.com/patent/US10369220B2

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- G01N 33/5023: {on expression patterns}
- G01N 33/5047: {Cells of the immune system}
- G01N 33/505: {involving T-cells}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method of treating a subject having a deficient immune response is described. The method includes administering a therapeutically effective amount of non-immune drug, or an analog or metabolite thereof, known to induce one or more autoimmune syndromes to the subject. Drugs known to induce one or more autoimmune syndromes, such as lupus-like syndromes, include immune checkpoint inhibitor blockers. Methods of identifying drugs capable of enhancing immunity are also described.

## Claims

### Claim 1

A method of enhancing the immune responsiveness of a subject having a deficient immune response, comprising administering to the subject a therapeutically effective amount of a drug known to induce one or more autoimmune syndromes, or an analog thereof, which is also known to induce one or more autoimmune syndromes.

### Claim 2 (depends on 1)

The method of claim 1, wherein the drug is a drug selected from the group consisting of anti-arrhythmic drugs, anticoagulants, antihistamines, anti-seizure drugs, antihypertensive drugs, anti-inflammatory drugs, antibiotics, cholesterol-lowering drugs, hormonal drugs, laxatives, proton-pump inhibitors, psychiatric drugs, calcium channel blockers, vasodilators, anti-platelet drugs, and chelating agents.

### Claim 3 (depends on 1)

The method of claim 1, wherein the drug is an immune checkpoint inhibitor blocker.

### Claim 4 (depends on 1)

The method of claim 1, wherein the autoimmune syndrome is a lupus-like syndrome.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject has a disease responsive to immune stimulation.

### Claim 6 (depends on 5)

The method of claim 5, wherein the disease responsive to immune stimulation is selected from the group consisting of cancer, infection, immunodeficiency, immunosuppression, and Alzheimer's disease.

### Claim 7 (depends on 5)

The method of claim 5, wherein the subject has been diagnosed with cancer.

### Claim 8 (depends on 5)

The method of claim 5, wherein the subject has been diagnosed with a viral infection.

### Claim 9 (depends on 5)

The method of claim 5, wherein the subject has been diagnosed with a bacterial infection.

### Claim 10 (depends on 6)

The method of claim 6, wherein the subject has primary immunodeficiency or immunodeficiency acquired from infection.

### Claim 11 (depends on 6)

The method of claim 6, wherein the subject has immunosuppression caused by aging, alcoholism, trauma, surgery, transplantation, splenectomy, diabetes, hepatic insufficiency, or protein-losing enteropathy.

### Claim 12 (depends on 6)

The method of claim 6, further comprising administering to the subject a therapeutically effective amount of a pharmaceutical agent for treatment of the disease to the subject in combination with the drug known to induce one or more autoimmune syndromes, or an analog thereof, which is also known to induce one or more autoimmune syndromes.

### Claim 13 (depends on 1)

The method of claim 1, wherein a plurality of drugs known to induce one or more autoimmune syndromes are administered to the subject.

### Claim 14 (depends on 1)

The method of claim 1, further comprising taking one or more blood samples to assess the immune responsiveness of the subject after administering to the subject a therapeutically effective amount of drug known to induce one or more autoimmune syndromes, or an analog thereof, which is also known to induce one or more autoimmune syndromes.